CHORD1 CHOlesterol Lowering and Residual Risk in Diabetes Type 1

Brief description of study

This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question. This study will recruit 125 participants with Type 1 Diabetes (T1D) to:

  • Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal)
  • Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases), and
  • Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.


    • Clinical Study Identifier: s22-01095
    ClinicalTrials.gov Identifier: NCT05641753
    Principal Investigator: Ira J Goldberg.
    Other Investigators: Chiara Giannarelli, Jeffrey S Berger, Michael Seth Garshick.


    If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

    Contact the research team to learn more about this study.

    By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.